QUANTITATIVE METABOLIC PARAMETERS EVALUATION IN PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMAS TREATED WITH ANTI‐CD19 CAR T‐CELLS

Introduction: Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is an effective therapy for relapsed/refractory (R/R) aggressive B-cell lymphomas and predictive biomarkers of response are required. Quantitative metabolic parameters from 18-FDG PET-CT scan are emerging tools able to predict outcome in aggressive lymphomas, but their value in the CAR T setting is still under investigation. Methods: We conducted an observational...